ClinicalTrials.gg
RecruitingNCT04362618KOA-PAINUpdated May 30, 2023

Exercise Therapy for Osteoarthritis Pain: How Does it Work?

An interventional study of Muscle Strengthening Training and Behavioral graded activity in Knee Osteoarthritis, sponsored by Vrije Universiteit Brussel. Recruiting at 1 site in Belgium. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-05-30.

Sponsored by Vrije Universiteit Brussel · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 10 months ago, but the record still lists the study as recruiting.
  • Started Mar 2020; still recruiting 6 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Osteoarthritis, Knee with a site in Belgium — 6 open to participants now, 11 under way, none of them phase 3. Osteoarthritis, Knee · Belgium.

Planned enrollment
19th of 38
90 · median 86
Started
2020
with 5 others
No phase
25 of 46
6 open now
Primary completion
2023-12
later than 1 of 10 live
Registered
27th of 46
by date
Lead sponsor
2 of 46
Vrije Universiteit Brussel

Among the 46 studies in Osteoarthritis, Knee with a site in Belgium, this one is the 19th largest by planned enrollment of the 38 interventional ones that give a count, is one of 6 that started in 2020, is one of 25 with no phase, reaches primary completion later than 1 of the 10 other live ones, and was the 27th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

6 of the 46 studies in Osteoarthritis, Knee with a site in Belgium are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Osteoarthritis, Knee with a site in Belgium, or all of them as a file.
02

Study summary

International guidelines recommend exercise as the first choice treatment for knee osteoarthritis (KOA). Muscle strengthening training (MST) and behavioural graded activity (BGA) show comparable effects on KOA pain, but the mechanisms of action are unclear. Understanding these mechanisms is necessary to tailor exercise therapy towards specific mediators and thereby optimize treatment effects. Based on previous studies, both exercise-induced anti-inflammation and endogenous analgesia are promising pathways for pain reduction after exercise therapy. This study aims to examine (anti)-inflammation and endogenous analgesia as mediators for the effect of MST and/or BGA on pain in patients with KOA. Therefore, a 3-arm randomized clinical trial is established: 12 weeks of muscle strengthening training, behavioural graded activity or control. Mediator analysis will be performed. Unravelling the mechanisms of action of exercise therapy in KOA will not only be extremely valuable for researchers, but also for exercise immunology and pain scientists. The results of this research will also find their way into clinical practice: thanks to the current project, tailoring exercise therapy programs towards specific mechanistic factors and thereby optimizing treatment effects will be at the horizon for patients suffering from KOA.

03

Conditions studied

  • Knee Osteoarthritis

Keywords

  • Osteoarthritis
  • Exercise
  • Acute effects
  • Inflammation
  • Endogenous hypoalgesia
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. KOA according to the clinical American College of Rheumatology (ACR) criteria. The clinical ACR criteria for KOA are: knee pain and at least 3 of the 6 following features: age ≥50, morning stiffness \<30 minutes, crepitus, bony tenderness, bony enlargement, no palpable warmth. KOA will be confirmed with radiographs, including anterior-posterior (AP) and medio-lateral (ML) radiographs for imaging the tibiofemoral joint, and an axial view for imaging the patellofemoral joint. Kellgren and Lawrence (K\&L) grading system for OA will be applied, with K\&L grade 2 or higher defined as OA; radiographic KOA is defined as definite osteophytes and possible joint space narrowing.
  2. pain, nominated by the patient as 3 /10 or higher on a visual analogue scale on most days of the last 3 months
  3. aged ≥ 50 years.

Exclusion criteria

Exclusion Criteria:

  1. treatment with exercise therapy or joint infiltrations (e.g., , hyaluronic acid) in the preceding 6 months;
  2. being on a waiting list for knee replacement;
  3. any for exercise therapy as established by the treating physician;
  4. corticosteroid infiltrations in the last 6 months;
  5. cognitive impairment (unable to understand the test instructions and/or score \<23/30);
  6. unable to understand the Dutch language;
  7. inflammation unrelated to OA (e.g. due to acute or chronic infection) established by CRP>10mg/L.
  8. presence of a disorder and/or medication that influences pain and/or the immune system
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Muscle Strengthening Training (MST)-group

    Subjects allocated to the MST group (n=30) will perform a muscle strengthening training program of 12 weeks.

    Other: Muscle Strengthening Training

  • Experimental
    Behavioral Graded Activity (BGA)-group

    Subjects allocated to the BGA group (n=30) will perform a rehabilitation program according to the principles of behavioural graded activity for a period of 12 weeks.

    Behavioral: Behavioral graded activity

  • No intervention
    Control group

    Subjects allocated to the control group (n=30) have to maintain their current life-style and treatment (if any) and to refrain from other new interventions during 24 weeks.

Interventions

  • OtherMuscle Strengthening Training

    Muscle strengthening training will take place for a period of 12 weeks, in which participants will have 36 exercise sessions (18 at the hospital under supervision of a physiotherapist; 18 unsupervised at home) planned. Muscles of the leg (i.e. quadriceps, hip ab- and adductors) will be trained at 3 set of 10 repetitions at 80% of 1RM with the use of elastic bands. 1RM will be assessed at baseline and the exercise intensity will be progressively increased by 10% of 1RM every two sessions from 50 up to 70-80 % of 1RM. Every 6 sessions, the 1RM will be reassessed and the training resistances will be adapted.

  • BehavioralBehavioral graded activity

    Subjects will receive a behavioural treatment integrated within the concepts of operant conditioning with exercise therapy for a period of 12 weeks, in which the subjects will have maximum 36 BGA sessions (min. 13- max. 18 at the hospital under supervision of a physiotherapist; 18 unsupervised at home) planned. The purpose of BGA is to increase the level of activities in a time-contingent manner and increase the level of physical activity in the subject's daily lives. BGA consists of 3 phases: pain education (phase 1), treatment phase in which subjects increase their level of activity gradually (phase 2) and integration of learned principles in daily live (phase 3).

06

What researchers measure

Primary outcomes

  1. Knee pain as primary study outcome

    Pain is the primary outcome as it is the primary and most disabling symptom in OA. The pain subscale of the WOMAC Osteoarthritis Index LK3.0 questionnaire will be used for the assessment of pain severity. The Knee injury and Osteoarthritis Outcome Score (KOOS) includes WOMAC Osteoarthritis Index LK3.0 in its complete and original format (with permission). WOMAC (and therefore the pain and symptoms subscale of the KOOS) is a valid tool for subjects with KOA. The KOOS is proven to generate valid and reliable scores.

    Time frame: Baseline

  2. Knee pain as primary study outcome

    Pain is the primary outcome as it is the primary and most disabling symptom in OA. The pain subscale of the WOMAC Osteoarthritis Index LK3.0 questionnaire will be used for the assessment of pain severity. The Knee injury and Osteoarthritis Outcome Score (KOOS) includes WOMAC Osteoarthritis Index LK3.0 in its complete and original format (with permission). WOMAC (and therefore the pain and symptoms subscale of the KOOS) is a valid tool for subjects with KOA. The KOOS is proven to generate valid and reliable scores.

    Time frame: during intervention: week 2 (acute)

  3. Knee pain as primary study outcome

    Pain is the primary outcome as it is the primary and most disabling symptom in OA. The pain subscale of the WOMAC Osteoarthritis Index LK3.0 questionnaire will be used for the assessment of pain severity. The Knee injury and Osteoarthritis Outcome Score (KOOS) includes WOMAC Osteoarthritis Index LK3.0 in its complete and original format (with permission). WOMAC (and therefore the pain and symptoms subscale of the KOOS) is a valid tool for subjects with KOA. The KOOS is proven to generate valid and reliable scores.

    Time frame: during intervention: week 10 (acute)

  4. Knee pain as primary study outcome

    Pain is the primary outcome as it is the primary and most disabling symptom in OA. The pain subscale of the WOMAC Osteoarthritis Index LK3.0 questionnaire will be used for the assessment of pain severity. The Knee injury and Osteoarthritis Outcome Score (KOOS) includes WOMAC Osteoarthritis Index LK3.0 in its complete and original format (with permission). WOMAC (and therefore the pain and symptoms subscale of the KOOS) is a valid tool for subjects with KOA. The KOOS is proven to generate valid and reliable scores.

    Time frame: post-intervention: week 13

  5. Knee pain as primary study outcome

    Pain is the primary outcome as it is the primary and most disabling symptom in OA. The pain subscale of the WOMAC Osteoarthritis Index LK3.0 questionnaire will be used for the assessment of pain severity. The Knee injury and Osteoarthritis Outcome Score (KOOS) includes WOMAC Osteoarthritis Index LK3.0 in its complete and original format (with permission). WOMAC (and therefore the pain and symptoms subscale of the KOOS) is a valid tool for subjects with KOA. The KOOS is proven to generate valid and reliable scores.

    Time frame: post-intervention: week 26

  6. Knee pain as primary study outcome

    Pain is the primary outcome as it is the primary and most disabling symptom in OA. The pain subscale of the WOMAC Osteoarthritis Index LK3.0 questionnaire will be used for the assessment of pain severity. The Knee injury and Osteoarthritis Outcome Score (KOOS) includes WOMAC Osteoarthritis Index LK3.0 in its complete and original format (with permission). WOMAC (and therefore the pain and symptoms subscale of the KOOS) is a valid tool for subjects with KOA. The KOOS is proven to generate valid and reliable scores.

    Time frame: post-intervention: week 64

Secondary outcomes

  1. Different subtypes of pain: pain

    Pain will be measured using the Visual analogue scale (VAS).

    Time frame: Baseline, during intervention (week 2 and 10), post-intervention (week 13, 26 and 64)

  2. Different subtypes of pain: intermittent pain

    Intermittent pain will be measured using a short and easily applicable self-reported measure, i.e. intermittent and constant pain (ICOAP).

    Time frame: Baseline, during intervention (week 2 and 10), post-intervention (week 13, 26 and 64)

  3. Different subtypes of pain: constant pain

    Constant pain, will be measured using a short and easily applicable self-reported measure, i.e. Intermittent and constant pain (ICOAP).

    Time frame: Baseline, during intervention (week 2 and 10), post-intervention (week 13, 26 and 64)

  4. Different subtypes of pain: central sensitization

    Central sensitization will be measured using an easily applicable self-reported measure i.e. Central Sensitization Inventory (CSI).

    Time frame: Baseline, during intervention (week 2 and 10), post-intervention (week 13, 26 and 64)

  5. Function in daily living (KOOS subscale)

    Function in daily living will be measured using self-reported measures. The KOOS function in daily living (ADL) subscale and functioning in sports and recreation subscale are reliable and valid scales to measure function in people with osteoarthritis. The patient global assessment (PGA) is a recommended questionnaire in clinical trials of rehabilitation interventions for OA and it measures the improvement or deterioration of their condition.

    Time frame: Baseline, post-intervention (week 13, 26 and 64)

  6. Function in daily living (PGA)

    Function in daily living will be measured using self-reported measures. The patient global assessment (PGA) is a recommended questionnaire in clinical trials of rehabilitation interventions for OA and it measures the improvement or deterioration of their condition.

    Time frame: Assessed at baseline and post-intervention (at week 13, 26 and 64)

  7. Treatment adherence

    Patient adherence for the treatment sessions will be calculated as the ratio of the number of treatment sessions that were actually carried out versus the number of prescribed sessions. Compliance will be calculated as the ratio of the total training duration (recorded in the logbooks) versus the prescribed total training duration, multiplied by 100.

    Time frame: During the intervention (week 1-12) and at week 13

  8. Treatment compliance

    Compliance will be calculated as the ratio of the total training duration (recorded in the logbooks) versus the prescribed total training duration, multiplied by 100.

    Time frame: During the intervention (week 1-12) and at week 13

  9. Health care cost effectiveness

    Medical consumption, the type, dose, method of administration and frequency of analgesic, NSAID or symptom-modifying medication, as well as surgeries (total or partial knee replacements) will be recorded. Health care use will be evaluated using the combination of three questionnaires: (1) the Medical Consumption Questionnaire (2) the Productivity Cost Questionnaire and (3) the EuroQol EQ-5D.

    Time frame: Assessed at baseline, at week 13, 26 and 64

Other outcomes

  1. Pain catastrophizing (explanatory outcome)

    Pain catastrophizing will be assessed using the Pain Catastrophizing Scale (PCS-DV).

    Time frame: Assessed at baseline, at week 13, 26 and 64

  2. Pain hypervigilance (explanatory outcome)

    Pain hypervigilance will be assessed using the Pain Vigilance and Awareness Questionnaire (PVAQ).

    Time frame: Assessed at baseline, at week 13, 26 and 64

  3. Illness perceptions (explanatory outcome)

    Illness perceptions will be assessed using the Illness Perception Questionnaire-revised (IPQ-R).

    Time frame: Assessed at baseline, at week 13, 26 and 64

  4. Dietary intake (explanatory outcome)

    Dietary intake will be assessed with the use of the Food Frequency Questionnaire (FFQ).

    Time frame: Assessed at baseline, at week 13, 26 and 64

  5. Inflammation (as treatment mediator)

    Inflammation will be tested by a blood-based biomarker panel (e.g. ELISA) for chronic low-grade inflammatory profile.

    Time frame: Assessments will be performed at baseline, during intervention (at week 2 or week 3 and at week 10 or week 11; pre- and post-treatment for the acute effects), at week 13 (at least 48 hours after the last intervention) and at week 64

  6. Endogenous analgesia as treatment mediator: electrical detection threshold

    Endogenous pain modulation will be evaluated by determining the electrical detection threshold. Electrical stimulation (Surpass LT Stimulator) will start at 0mA and will be gradually increased until the patient is experiencing a faint sensation.

    Time frame: Assessments will be performed at baseline, during intervention (at week 2 or week 3 and at week 10 or week 11; pre- and post-treatment for the acute effects), and at week 13 (at least 48 hours after the last intervention) and week 64

  7. Endogenous analgesia as treatment mediator: electrical pain threshold

    Endogenous pain modulation will be evaluated by determining the electrical pain threshold. Electrical stimulation (Surpass LT Stimulator) will start at 0 mA and will be gradually increased until the patient is experiencing the stimulus as painful.

    Time frame: Assessments will be performed at baseline, during intervention (at week 2 or week 3 and at week 10 or week 11; pre- and post-treatment for the acute effects), and at week 13 (at least 48 hours after the last intervention) and at week 64

  8. Endogenous analgesia as treatment mediator: temporal summation

    Endogenous pain facilitation will be evaluated by the temporal summation paradigm. Electrical stimuli (Surpass LT Stimulator) will be given at the intensity (mA) of the electrical pain threshold. A verbal numeric rating scale (VNRS) from 0 to 10 will be asked at the first stimulus, at the middle and at the last electrical stimulus.

    Time frame: Assessments will be performed at baseline, during intervention (at week 2 or week 3 and at week 10 or week 11; pre- and post-treatment for the acute effects), at week 13 (at least 48 hours after the last intervention) and at week 64

  9. Endogenous analgesia as treatment mediator: conditioned pain modulation

    The efficacy of endogenous analgesia will be evaluated by the conditioned pain modulation paradigm. Conditioned pain modulation will be tested with the electrical stimulator as test stimulus and the cold pressor (12 °C) as conditioning stimulus. The difference between the electrical pain threshold (baseline) and the electrical pain threshold during the cold pressor (baseline + cold pressor) is called the conditioned pain modulation effect. After electrical stimulation (Surpass LT Stimulator), a VNRS score from 0 to 10 will be asked.

    Time frame: Assessments will be performed at baseline, and at week 13 (at least 48 hours after the last intervention) and at week 64.

  10. Endogenous analgesia as treatment mediator: offset-analgesia

    Endogenous analgesia will be assessed by offset analgesia. Offset analgesia can be described as the disproportionately large decrease in perceived pain following slight decreases in electrical intensity. Painful electrical stimuli (Surpass LT Stimulator) will be given to the patients into 3 time intervals. The electrical intensity of time interval 1 and 3 will be the same, while the electrical intensity of time interval 2 will be higher. Participants need to report their intensity of pain according to the visual analogue scale ranging from 0 to 10 during the 3 intervals.

    Time frame: Assessments will be performed at baseline and at week 13 (at least 48 hours after the last intervention) and at week 64.

07

Study locations

1 of 1 sites recruiting
  • Vrije Universiteit Brussel (VUB)
    Jette, Brussels Capital Region 1090, Belgium
    Recruiting
    • Ivan Bautmans, PhD · Contactivan.bautmans@vub.be · +3224774207
    • Sofie Puts, MSc · Sub investigator
    • Lynn Leemans, MSc · Sub investigator
    • Laurence Leysen, PhD · Sub investigator
    • David Beckwée (prof), PhD · Sub investigator
    • Jo Nijs (prof), PhD · Sub investigator
    • Ivan Bautmans (prof), PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2020 (actual). Primary completion is estimated for Dec 2023, 45 months after the start.

Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 45 months is above that.

Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2020
First posted
Apr 27, 2020
StartActual
Mar 5, 2020
Primary completionEst.
Dec 31, 2023
CompletionEst.
Dec 31, 2023
Last update
May 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04362618
Collaborators
Universitair Ziekenhuis Brussel, AZ St.-Dimpna Geel
Responsible party
Prof. Ivan Bautmans (Prof. dr., Vrije Universiteit Brussel) — Principal investigator
First posted
Apr 27, 2020
Start date
Mar 5, 2020
Primary completion
Dec 31, 2023 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
May 30, 2023

Study contacts

Ivan Bautmans, PhD
Contact
ivan.bautmans@vub.be
+3224774207
Ivan Bautmans, PhD
principal investigator · Gerontology department (GERO) and Frailty in Ageing (FRIA) research department, Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, B-1090 Brussels, Belgium

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion